{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T05:26:05Z","timestamp":1787030765335,"version":"build-2736575974"},"reference-count":97,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T00:00:00Z","timestamp":1780876800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T00:00:00Z","timestamp":1780876800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s10067-026-08211-x","type":"journal-article","created":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T19:04:18Z","timestamp":1780945458000},"page":"4747-4761","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cellular therapies in systemic lupus erythematosus: recent progress and future directions"],"prefix":"10.1007","volume":"45","author":[{"given":"Ansaam","family":"Daoud","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omer N.","family":"Pamuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,8]]},"reference":[{"issue":"17","key":"8211_CR1","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1001\/jama.2024.2315","volume":"331","author":"CH Siegel","year":"2024","unstructured":"Siegel CH, Sammaritano LR (2024) Systemic lupus erythematosus: a review. JAMA 331(17):1480\u20131491","journal-title":"JAMA"},{"issue":"10441","key":"8211_CR2","doi-asserted-by":"publisher","first-page":"2326","DOI":"10.1016\/S0140-6736(24)00398-2","volume":"403","author":"A Hoi","year":"2024","unstructured":"Hoi A, Igel T, Mok CC, Arnaud L (2024) Systemic lupus erythematosus. Lancet 403(10441):2326\u20132338","journal-title":"Lancet"},{"issue":"6","key":"8211_CR3","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1002\/art.41632","volume":"73","author":"PM Izmirly","year":"2021","unstructured":"Izmirly PM, Parton H, Wang L, McCune WJ, Lim SS, Drenkard C, Ferucci ED, Dall\u2019Era M, Gordon C, Helmick CG, Somers EC (2021) Prevalence of systemic lupus erythematosus in the united states: estimates from a meta-analysis of the centers for disease control and prevention national lupus registries. Arthritis Rheumatol 73(6):991\u2013996","journal-title":"Arthritis Rheumatol"},{"key":"8211_CR4","unstructured":"-Centers for Disease Control and Prevention. Lupus. [Accessed March 17, 2024]. Available from: https:\/\/www.cdc.gov\/chronicdisease\/resources\/publications\/factsheets\/lupus.htm)"},{"issue":"8","key":"8211_CR5","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1002\/acr.25509","volume":"77","author":"A Daoud","year":"2025","unstructured":"Daoud A, Dweik L, Pamuk O (2025) Temporal trends and demographic insights into mortality from systemic lupus erythematosus, 1999\u20132020. Arthritis Care Res (Hoboken) 77(8):988\u2013997","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"7","key":"8211_CR6","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1016\/j.molmed.2017.05.006","volume":"23","author":"VR Moulton","year":"2017","unstructured":"Moulton VR, Suarez-Fueyo A, Meidan E, Li H, Mizui M, Tsokos GC (2017) Pathogenesis of human systemic lupus erythematosus: a cellular perspective. Trends Mol Med 23(7):615\u2013635","journal-title":"Trends Mol Med"},{"issue":"15","key":"8211_CR7","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1056\/NEJMoa2410965","volume":"392","author":"RA Furie","year":"2025","unstructured":"Furie RA, Rovin BH, Garg JP, Santiago MB, Aroca-Mart\u00ednez G, Zuta Santill\u00e1n AE et al (2025) Efficacy and safety of obinutuzumab in active lupus nephritis. N Engl J Med 392(15):1471\u20131483","journal-title":"N Engl J Med"},{"key":"8211_CR8","doi-asserted-by":"publisher","unstructured":"Furie RA, Dall'Era M, Vital EM, Garg JP, Irazoque Palazuelos F, Zuta Santill\u00e1n AE, Ravelo-Hern\u00e1ndez J, Santiago MB, Zazueta Montiel B, Botha S, Leszczy\u0144ski P, de Souza VA, Sicsik SA, Bellatin L, Naidoo A, Amoura Z, D'Agostino MA, Kumar S, Workeneh B, Rae J, Mao HA, Erblang F, Meier O, Maller JC, Askanase AD, ALLEGORY Trial Investigators (2026) Efficacy and safety of obinutuzumab in active systemic lupus erythematosus. N Engl J Med. https:\/\/doi.org\/10.1056\/NEJMoa2516150","DOI":"10.1056\/NEJMoa2516150"},{"key":"8211_CR9","doi-asserted-by":"publisher","first-page":"1476859","DOI":"10.3389\/fimmu.2024.1476859","volume":"15","author":"J Zhou","year":"2024","unstructured":"Zhou J, Lei B, Shi F, Luo X, Wu K, Xu Y, Zhang Y, Liu R, Wang H, Zhou J, He X (2024) CAR T-cell therapy for systemic lupus erythematosus: current status and future perspectives. Front Immunol 15:1476859","journal-title":"Front Immunol"},{"key":"8211_CR10","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1038\/s41577-024-01035-3","volume":"24","author":"JB Chung","year":"2024","unstructured":"Chung JB, Brudno JN, Borie D, Kochenderfer JN (2024) Chimeric antigen receptor T-cell therapy for autoimmune disease. Nat Rev Immunol 24:830\u2013845","journal-title":"Nat Rev Immunol"},{"key":"8211_CR11","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1056\/NEJMra1706169","volume":"379","author":"CH June","year":"2018","unstructured":"June CH, Sadelain M (2018) Chimeric Antigen Receptor Therapy. N Engl J Med 379:64\u201373","journal-title":"N Engl J Med"},{"key":"8211_CR12","doi-asserted-by":"publisher","first-page":"10024","DOI":"10.1073\/pnas.86.24.10024","volume":"86","author":"G Gross","year":"1989","unstructured":"Gross G, Waks T, Eshhar Z (1989) Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity. Proc Natl Acad Sci U S A 86:10024\u201310028","journal-title":"Proc Natl Acad Sci U S A"},{"key":"8211_CR13","doi-asserted-by":"publisher","first-page":"1924","DOI":"10.1001\/jama.2024.19462","volume":"332","author":"JN Brudno","year":"2024","unstructured":"Brudno JN, Maus MV, Hinrichs CS (2024) CAR T cells and T-cell therapies for cancer: a translational science review. JAMA 332:1924\u20131935","journal-title":"JAMA"},{"key":"8211_CR14","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1001\/jamaneurol.2024.3818","volume":"82","author":"FS Ismail","year":"2025","unstructured":"Ismail FS, Gallus M, Meuth SG, Okada H, Hartung HP, Melzer N (2025) Current and future roles of chimeric antigen receptor T-cell therapy in neurology: a review. JAMA Neurol 82:93\u2013103","journal-title":"JAMA Neurol"},{"key":"8211_CR15","doi-asserted-by":"crossref","unstructured":"Wrona E, Potemski P (2019) A novel immunotherapy \u2014 the history of CAR T-cell therapy. Oncol Clin Pract 15(4):202\u2013207","DOI":"10.5603\/OCP.2019.0016"},{"key":"8211_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2025.102596","volume":"95","author":"W Nie","year":"2025","unstructured":"Nie W, Yang X, Ma M, Xu X, Hou J (2025) Chimeric antigen receptor T cell therapy for autoimmune diseases. Curr Opin Immunol 95:102596","journal-title":"Curr Opin Immunol"},{"key":"8211_CR17","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1073\/pnas.90.2.720","volume":"90","author":"Z Eshhar","year":"1993","unstructured":"Eshhar Z, Waks T, Gross G, Schindler DG (1993) Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. Proc Natl Acad Sci U S A 90:720\u2013724","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"8211_CR18","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.coi.2009.02.009","volume":"21","author":"M Sadelain","year":"2009","unstructured":"Sadelain M, Brentjens R, Rivi\u00e8re I (2009) The promise and potential pitfalls of chimeric antigen receptors. Curr Opin Immunol 21(2):215\u2013223","journal-title":"Curr Opin Immunol"},{"issue":"22","key":"8211_CR19","doi-asserted-by":"publisher","first-page":"10995","DOI":"10.1158\/0008-5472.CAN-06-0160","volume":"66","author":"CM Kowolik","year":"2006","unstructured":"Kowolik CM, Topp MS, Gonzalez S, Pfeiffer T, Olivares S, Gonzalez N, Smith DD, Forman SJ, Jensen MC, Cooper LJ (2006) CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cells. Cancer Res 66(22):10995\u201311004","journal-title":"Cancer Res"},{"issue":"8","key":"8211_CR20","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1038\/mt.2009.83","volume":"17","author":"MC Milone","year":"2009","unstructured":"Milone MC, Fish JD, Carpenito C, Carroll RG, Binder GK, Teachey D et al (2009) Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo. Mol Ther 17(8):1453\u201364","journal-title":"Mol Ther"},{"issue":"8","key":"8211_CR21","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.1158\/1078-0432.CCR-15-1433","volume":"22","author":"MV Maus","year":"2016","unstructured":"Maus MV, June CH (2016) Making better chimeric antigen receptors for adoptive T-cell therapy. Clin Cancer Res 22(8):1875\u201384","journal-title":"Clin Cancer Res"},{"issue":"11","key":"8211_CR22","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1089\/hum.2009.142","volume":"20","author":"G Dotti","year":"2009","unstructured":"Dotti G, Savoldo B, Brenner M (2009) Fifteen years of gene therapy based on chimeric antigen receptors: \u201care we nearly there yet?\u201d Hum Gene Ther 20(11):1229\u201339","journal-title":"Hum Gene Ther"},{"issue":"8","key":"8211_CR23","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.1158\/1078-0432.CCR-15-1433","volume":"22","author":"MV Maus","year":"2016","unstructured":"Maus MV, June CH (2016) Making better chimeric antigen receptors for adoptive T-cell therapy. Clin Cancer Res 22(8):1875\u201384","journal-title":"Clin Cancer Res"},{"issue":"11","key":"8211_CR24","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1038\/s41577-024-01035-3","volume":"24","author":"JB Chung","year":"2024","unstructured":"Chung JB, Brudno JN, Borie D, Kochenderfer JN (2024) Chimeric antigen receptor T-cell therapy for autoimmune disease. Nat Rev Immunol 24(11):830\u2013845","journal-title":"Nat Rev Immunol"},{"key":"8211_CR25","unstructured":"Kagoya Y, Tanaka S, Guo T, et al (2018) A novel chimeric antigen receptor design that incorporates the IL-2 receptor \u03b2-chain cytoplasmic domain enhances antitumor activity through STAT5 signaling. Sci Transl Med 10(426):eaao5931"},{"issue":"11","key":"8211_CR26","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1158\/1535-7163.MCT-23-0043","volume":"22","author":"AL Rodr\u00edguez Gil de Montes","year":"2023","unstructured":"Rodr\u00edguez Gil de Montes AL, Spencer LM (2023) Chimeric antigen receptor T cells: immunotherapy for the treatment of leukemia, lymphoma, and myeloma. Mol Cancer Ther 22(11):1261\u20131269","journal-title":"Mol Cancer Ther"},{"issue":"12","key":"8211_CR27","doi-asserted-by":"publisher","first-page":"1724","DOI":"10.1136\/ard.2007.083162","volume":"67","author":"D Albert","year":"2008","unstructured":"Albert D, Dunham J, Khan S, Stansberry J, Kolasinski S, Tsai D et al (2008) Variability in the biological response to anti-CD20 B cell depletion in systemic lupus erythaematosus. Ann Rheum Dis 67(12):1724\u201331","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"8211_CR28","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1038\/s41584-024-01139-z","volume":"20","author":"G Schett","year":"2024","unstructured":"Schett G, M\u00fcller F, Taubmann J, Mackensen A, Wang W, Furie RA et al (2024) Advancements and challenges in CAR T cell therapy in autoimmune diseases. Nat Rev Rheumatol 20(9):531\u2013544","journal-title":"Nat Rev Rheumatol"},{"issue":"16","key":"8211_CR29","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.3390\/cells14161242","volume":"14","author":"P Anyfanti","year":"2025","unstructured":"Anyfanti P, Evangelidis P, Kotsiou N, Papakonstantinou A, Eftychidis I, Sakellari I et al (2025) Chimeric antigen receptor T cell immunotherapy for autoimmune rheumatic disorders: where are we now?. Cells 14(16):1242","journal-title":"Cells"},{"issue":"2","key":"8211_CR30","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1038\/s41584-024-01210-9","volume":"21","author":"M Stockfelt","year":"2025","unstructured":"Stockfelt M, Teng YKO, Vital EM (2025) Opportunities and limitations of B cell depletion approaches in SLE. Nat Rev Rheumatol 21(2):111\u2013126","journal-title":"Nat Rev Rheumatol"},{"issue":"482","key":"8211_CR31","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aav1648","volume":"11","author":"R Kansal","year":"2019","unstructured":"Kansal R, Richardson N, Neeli I, Khawaja S, Chamberlain D, Ghani M, Ghani Q-u-A et al (2019) Sustained B cell depletion by CD19-targeted CAR T cells is a highly effective treatment for murine lupus. Sci Transl Med 11(482):eaav1648","journal-title":"Sci Transl Med"},{"issue":"8","key":"8211_CR32","doi-asserted-by":"publisher","first-page":"1896","DOI":"10.1038\/s41423-020-0472-1","volume":"18","author":"X Jin","year":"2021","unstructured":"Jin X, Xu Q, Pu C, Zhu K, Lu C, Jiang Y, Xiao L, Han Y, Lu L (2021) Therapeutic efficacy of anti-CD19 CAR T-cells in a mouse model of systemic lupus erythematosus. Cell Mol Immunol 18(8):1896\u20131903","journal-title":"Cell Mol Immunol"},{"issue":"6","key":"8211_CR33","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1056\/NEJMc2107725","volume":"385","author":"D Mougiakakos","year":"2021","unstructured":"Mougiakakos D, Kr\u00f6nke G, V\u00f6lkl S, Kretschmann S, Aigner M, Kharboutli S et al (2021) CD19-targeted CAR T cells in refractory systemic lupus erythematosus. N Engl J Med 385(6):567\u2013569","journal-title":"N Engl J Med"},{"issue":"10","key":"8211_CR34","doi-asserted-by":"publisher","first-page":"2124","DOI":"10.1038\/s41591-022-02017-5","volume":"28","author":"A Mackensen","year":"2022","unstructured":"Mackensen A, M\u00fcller F, Mougiakakos D, B\u00f6ltz S, Wilhelm A, Aigner M et al (2022) Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus. Nat Med 28(10):2124\u20132132","journal-title":"Nat Med"},{"key":"8211_CR35","doi-asserted-by":"publisher","first-page":"101104","DOI":"10.1016\/j.omtm.2023.08.023","volume":"31","author":"D Nunez","year":"2023","unstructured":"Nunez D, Patel D, Volkov J, Wong S, Vorndran Z, M\u00fcller F et al (2023) Cytokine and reactivity profiles in SLE patients following anti-CD19 CART therapy. Mol Ther Methods Clin Dev 31:101104","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"8","key":"8211_CR36","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1056\/NEJMoa2308917","volume":"390","author":"F M\u00fcller","year":"2024","unstructured":"M\u00fcller F, Taubmann J, Bucci L, Wilhelm A, Bergmann C, V\u00f6lkl S et al (2024) CD19 CAR T-cell therapy in autoimmune disease - a case series with follow-up. N Engl J Med 390(8):687\u2013700","journal-title":"N Engl J Med"},{"issue":"10","key":"8211_CR37","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1016\/j.ard.2025.06.2128","volume":"84","author":"Z Hu","year":"2025","unstructured":"Hu Z, Cai S, Yu Y, Chen Y, Wang B, Wang D, Yu F et al (2025) BCMA-targeted CAR T cell therapy can effectively induce disease remission in refractory lupus nephritis. Ann Rheum Dis 84(10):1675\u20131683","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"8211_CR38","doi-asserted-by":"publisher","first-page":"3725","DOI":"10.1038\/s41591-025-03937-8","volume":"31","author":"J Feng","year":"2025","unstructured":"Feng J, Huo D, Hong R, Jin X, Cao H, Shao M et al (2025) Co-infusion of CD19-targeting and BCMA-targeting CAR T-cells for treatment-refractory systemic lupus erythematosus: a phase 1 trial. Nat Med 31(11):3725\u20133736","journal-title":"Nat Med"},{"key":"8211_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2025.103489","volume":"157","author":"Y Wang","year":"2025","unstructured":"Wang Y, Yang S, Yu Y, Xia P, Xie C, Zhang C, Lu L (2025) Preliminary safety and efficacy of relmacabtagene autoleucel (relma-cel) in adults with moderately to severely active systemic lupus erythematosus: a phase I dose-escalation study. J Autoimmun 157:103489","journal-title":"J Autoimmun"},{"issue":"10","key":"8211_CR40","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1136\/ard-2024-225785","volume":"83","author":"W Wang","year":"2024","unstructured":"Wang W, He S, Zhang W, Zhang H, DeStefano VM, Wada M, Wang M et al (2024) BCMA-CD19 compound CAR T cells for systemic lupus erythematosus: a phase 1 open-label clinical trial. Ann Rheum Dis 83(10):1304\u20131314","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"8211_CR41","doi-asserted-by":"publisher","first-page":"e434","DOI":"10.1016\/S2665-9913(24)00377-1","volume":"7","author":"M Scherlinger","year":"2025","unstructured":"Scherlinger M, Nocturne G, Radic M, Launay D, Richez C, Bousso P et al (2025) CAR T-cell therapy in autoimmune diseases: where are we and where are we going? Lancet Rheumatol 7(6):e434\u2013e447","journal-title":"Lancet Rheumatol"},{"issue":"24","key":"8211_CR42","doi-asserted-by":"publisher","first-page":"2154","DOI":"10.1001\/jama.2023.8753","volume":"329","author":"AC Pecher","year":"2023","unstructured":"Pecher AC, Hensen L, Klein R, Schairer R, Lutz K, Atar D et al (2023) CD19-Targeting CAR T cells for myositis and interstitial lung disease associated with antisynthetase syndrome. JAMA 329(24):2154\u20132162","journal-title":"JAMA"},{"key":"8211_CR43","unstructured":"Search ClinicalTrials.gov for: Lupus Erythematosus, Systemic, Other terms: lupus, CAR-T | List Results | ClinicalTrials.gov"},{"issue":"12","key":"8211_CR44","doi-asserted-by":"publisher","first-page":"103687","DOI":"10.1016\/j.autrev.2024.103687","volume":"23","author":"T Alsuliman","year":"2024","unstructured":"Alsuliman T, Marjanovic Z, Rimar D, Tarte K, Avcin T, Hagen M, Schett G, Farge D (2024) Harnessing the potential of CAR T-cell in lupus treatment: from theory to practice. Autoimmun Rev 23(12):103687","journal-title":"Autoimmun Rev"},{"issue":"25","key":"8211_CR45","first-page":"01477","volume":"S2666\u20136367","author":"AY Cheema","year":"2025","unstructured":"Cheema AY, Ali HM, Maryam B, Aslam MF, Thiagarajan PS, Shahid D et al (2025) Under the hood: evidence-based review of allogeneic chimeric antigen receptor T cells for hematologic malignancies. Transplant Cell Ther S2666\u20136367(25):01477","journal-title":"Transplant Cell Ther"},{"issue":"6","key":"8211_CR46","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1002\/cpt.3241","volume":"115","author":"H Mody","year":"2024","unstructured":"Mody H, Sutaria DS, Miles D (2024) Clinical pharmacology considerations for the \u201coff-the-shelf\u201d allogeneic cell therapies. Clin Pharmacol Ther 115(6):1233\u20131250","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"8211_CR47","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/s13045-025-01737-8","volume":"18","author":"N Jiang","year":"2025","unstructured":"Jiang N, Yang Z, Miao H, Xing S, Wang S, Li N (2025) Recent advances in universal chimeric antigen receptor T cell therapy. J Hematol Oncol 18(1):82","journal-title":"J Hematol Oncol"},{"issue":"1","key":"8211_CR48","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.tips.2025.11.001","volume":"47","author":"YR Li","year":"2025","unstructured":"Li YR, Yang L (2025) Autologous, allogeneic, in vivo CAR for autoimmune diseases. Trends Pharmacol Sci 47(1):11\u20131","journal-title":"Trends Pharmacol Sci"},{"issue":"7","key":"8211_CR49","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1038\/nrd4597","volume":"14","author":"SJ van der Stegen","year":"2015","unstructured":"van der Stegen SJ, Hamieh M, Sadelain M (2015) The pharmacology of second-generation chimeric antigen receptors. Nat Rev Drug Discov 14(7):499\u2013509","journal-title":"Nat Rev Drug Discov"},{"issue":"11","key":"8211_CR50","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1038\/s41571-021-00530-z","volume":"18","author":"KM Cappell","year":"2021","unstructured":"Cappell KM, Kochenderfer JN (2021) A comparison of chimeric antigen receptors containing CD28 versus 4\u20131BB costimulatory domains. Nat Rev Clin Oncol 18(11):715\u2013727","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"8211_CR51","doi-asserted-by":"publisher","first-page":"38","DOI":"10.3390\/cancers13010038","volume":"13","author":"AS Davey","year":"2020","unstructured":"Davey AS, Call ME, Call MJ (2020) The influence of chimeric antigen receptor structural domains on clinical outcomes and associated toxicities. Cancers (Basel) 13(1):38","journal-title":"Cancers (Basel)"},{"issue":"6","key":"8211_CR52","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1038\/nm.3838","volume":"21","author":"AH Long","year":"2015","unstructured":"Long AH, Haso WM, Shern JF, Wanhainen KM, Murgai M, Ingaramo M et al (2015) 4\u20131BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors. Nat Med 21(6):581\u2013590","journal-title":"Nat Med"},{"issue":"7","key":"8211_CR53","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2025.115973","volume":"44","author":"MS Cook","year":"2025","unstructured":"Cook MS, King E, Flaherty KR, Siddika K, Papa S, Benjamin R, Schurich A (2025) CAR T-cells containing CD28 versus 4\u20131BB co-stimulatory domains show distinct metabolic profiles in patients. Cell Rep 44(7):115973","journal-title":"Cell Rep"},{"issue":"3","key":"8211_CR54","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1038\/s41573-019-0051-2","volume":"19","author":"S Depil","year":"2020","unstructured":"Depil S, Duchateau P, Grupp SA, Mufti G, Poirot L (2020) \u201cOff-the-shelf\u201d allogeneic CAR T cells: development and challenges. Nat Rev Drug Discov 19(3):185\u2013199","journal-title":"Nat Rev Drug Discov"},{"issue":"11","key":"8211_CR55","doi-asserted-by":"publisher","first-page":"3713","DOI":"10.1038\/s41591-025-03899-x","volume":"31","author":"X Wang","year":"2025","unstructured":"Wang X, Zhang Y, Wang H, Wu X, He C, Lin S et al (2025) Allogeneic CD19-targeting T cells for treatment-refractory systemic lupus erythematosus: a phase 1 trial. Nat Med 31(11):3713\u20133724","journal-title":"Nat Med"},{"key":"8211_CR56","doi-asserted-by":"crossref","unstructured":"Maternah A, Maternah B, Salameh O, Akkari A, Ghahramani N, Trivedi N (2025) Chimeric antigen receptor T cell therapy in systemic lupus erythematosus: mechanisms, clinical advances, and future directions. A comprehensive review. Clin Rev Allergy Immunol 68:103","DOI":"10.1007\/s12016-025-09114-6"},{"key":"8211_CR57","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1038\/s41571-024-00905-y","volume":"21","author":"M Goebeler","year":"2024","unstructured":"Goebeler M, Stuhler G, Bargou R (2024) Bispecific and multispecific antibodies in oncology: opportunities and challenges. Nat Rev Clin Oncol 21:539\u2013560","journal-title":"Nat Rev Clin Oncol"},{"key":"8211_CR58","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1097\/BOR.0000000000001062","volume":"37","author":"H Wobma","year":"2025","unstructured":"Wobma H, Chang JC, Prockop SE (2025) Releasing our model T - chimeric antigen receptor (CAR) T-cells for autoimmune indications. Curr Opin Rheumatol 37:128\u2013135","journal-title":"Curr Opin Rheumatol"},{"key":"8211_CR59","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1038\/s41591-024-02964-1","volume":"30","author":"L Bucci","year":"2024","unstructured":"Bucci L, Hagen M, Rothe T, Raimondo MG, Fagni F, Tur C et al (2024) Bispecific T-cell-engager therapy for refractory rheumatoid arthritis. Nat Med 30:1593\u20131601","journal-title":"Nat Med"},{"key":"8211_CR60","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.1038\/s41591-025-03718-3","volume":"31","author":"F Muller","year":"2025","unstructured":"Muller F, Wirsching A, Hagen M, Volkl S, Tur C, Raimondo MG et al (2025) BCMA CAR T cells in a patient with relapsing idiopathic inflammatory myositis after initial and repeat therapy with CD19 CAR T cells. Nat Med 31:1793\u20131797","journal-title":"Nat Med"},{"key":"8211_CR61","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1056\/NEJMc2407150","volume":"391","author":"T Alexander","year":"2024","unstructured":"Alexander T, Kronke J, Cheng Q, Keller U, Kronke G (2024) Teclistamat-induced remission in refractory systemic lupus erythematosus. N Engl J Med 391:864\u2013866","journal-title":"N Engl J Med"},{"key":"8211_CR62","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1136\/ard-2024-226142","volume":"84","author":"C Tur","year":"2025","unstructured":"Tur C, Eckstein M, Velden J, Rauber S, Bergmann AJ, Auth J et al (2025) CD19-CAR T-cell therapy induces deep tissue depletion of B cells. Ann Rheum Dis 84:106\u2013114","journal-title":"Ann Rheum Dis"},{"key":"8211_CR63","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1038\/s41577-025-01141-w","volume":"25","author":"T Junt","year":"2025","unstructured":"Junt T, Calzascia T, Traggiai E, da Costa AN, Gergely P, Schett G et al (2025) Defining immune reset: achieving sustained remission in autoimmune diseases. Nat Rev Immunol 25:528\u2013541","journal-title":"Nat Rev Immunol"},{"key":"8211_CR64","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2025.103369","volume":"151","author":"V Uppin","year":"2025","unstructured":"Uppin V, Gibbons H, Troje M, Feinberg D, Webber BR, Moriarity BS et al (2025) CAR T-cell targeting three receptors on autoreactive B cells for systemic lupus erythematosus therapy. J Autoimmunity 151:103369","journal-title":"J Autoimmunity"},{"key":"8211_CR65","doi-asserted-by":"publisher","first-page":"2080","DOI":"10.1002\/art.21138","volume":"52","author":"W Stohl","year":"2005","unstructured":"Stohl W, Xu D, Kim KS, Koss MN, Jorgensen TN, Deocharan B et al (2005) BAFF overexpression and accelerated glomerular disease in mice with an incomplete genetic predisposition to systemic lupus erythematosus. Arthritis Rheum 52:2080\u20132091","journal-title":"Arthritis Rheum"},{"key":"8211_CR66","first-page":"1004","volume":"111","author":"C Bossen","year":"2008","unstructured":"Bossen C, Cachero TG, Tardivel A, Ingold K, Willen I, Dobles M et al (2008) TACI, unlike BAFF-R, is solely activated by oligomeric BAFF and APRIL to support survival of activated B cells and plasmablasts. Blood Am J Hematol 111:1004\u20131012","journal-title":"Blood Am J Hematol"},{"key":"8211_CR67","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1002\/cti2.1047","volume":"8","author":"FB Vincent","year":"2019","unstructured":"Vincent FB, Kandane-Rathnayake R, Koelmeyer R, Hol AY, Harris J, Mackay F et al (2019) Analysis of serum B-cell activating factor from the tumor necrosis factor family (BAFF) and its soluble receptors in systemic lupus erythematosus. Clin Transl Immunology 8:1047","journal-title":"Clin Transl Immunology"},{"key":"8211_CR68","first-page":"2256","volume":"109","author":"J Zhou","year":"2024","unstructured":"Zhou J, Xu Y, Shu J, Jiang H, Huang I, Xu M et al (2024) GPIbalpha CAAR T cells function like a Trojan horse to eliminate autoreactive B cells to treat immune thrombocytopenia. Haematologica 109:2256\u20132270","journal-title":"Haematologica"},{"key":"8211_CR69","doi-asserted-by":"publisher","first-page":"1613878","DOI":"10.3389\/fimmu.2025.1613878","volume":"16","author":"D Wu","year":"2025","unstructured":"Wu D, Xu-Monette ZY, Zhou J, Yang K, Wang X, Fan Y et al (2025) CAR T-cell therapy in autoimmune diseases: a promising frontier on the horizon. Front Immunol 16:1613878","journal-title":"Front Immunol"},{"key":"8211_CR70","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1126\/science.aaf6756","volume":"353","author":"CT Ellebracht","year":"2016","unstructured":"Ellebracht CT, Bhoj VG, Nace A, Choi EJ, Mao X, Cho MJ et al (2016) Reengineering chimeric antigen receptor T cells for targeted therapy of autoimmune disease. Science 353:179\u2013184","journal-title":"Science"},{"key":"8211_CR71","doi-asserted-by":"publisher","first-page":"1841","DOI":"10.1182\/blood.2024025413","volume":"145","author":"D Mougiakakos","year":"2025","unstructured":"Mougiakakos D, Meyer EH, Schett G (2025) CAR T cells in autoimmunity: game changer or stepping stone. Blood 145:1841\u20131849","journal-title":"Blood"},{"key":"8211_CR72","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1038\/s41573-024-00959-8","volume":"23","author":"F Ramirez-Valle","year":"2024","unstructured":"Ramirez-Valle F, Maranville JC, Roy S, Plenge RM (2024) Sequential immunotherapy: towards cures for autoimmunity. Nat Rev Drug Discov 23:501\u2013524","journal-title":"Nat Rev Drug Discov"},{"key":"8211_CR73","doi-asserted-by":"publisher","unstructured":"Chen X, Liu K, Liu B, Li S, Wang Y, Du X, Weng J, Song B, Wu K, Lai P (2025) Challenges and strategies in clinical applications of CAR-T therapy for autoimmune diseases. J Hematol Oncol 19(1):1. https:\/\/doi.org\/10.1186\/s13045-025-01769-0","DOI":"10.1186\/s13045-025-01769-0"},{"key":"8211_CR74","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1038\/s41587-022-01637-z","volume":"41","author":"S Oh","year":"2023","unstructured":"Oh S, Mao X, Manfredo-Vieria S, Lee J, Patel D, Choi EJ et al (2023) Precision targeting of autoantigen-specific B cells in muscle-specific tyrosine kinase myasthenia gravis with chimeric autoantibody receptor T cells. Nat Biotechnol 41:1229\u20131238","journal-title":"Nat Biotechnol"},{"key":"8211_CR75","first-page":"2256","volume":"109","author":"J Zhou","year":"2024","unstructured":"Zhou J, Xu Y, Shu J, Jiang H, Huang I, Xu M et al (2024) GPIbalpha CAAR T cells function like a Trojan horse to eliminate autoreactive B cells to treat immune thrombocytopenia. Haematologica 109:2256\u20132270","journal-title":"Haematologica"},{"key":"8211_CR76","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1093\/cei\/uxae031","volume":"217","author":"K Shah","year":"2024","unstructured":"Shah K, Leandro M, Cragg M, Kollert F, Schuler F, Klein C et al (2024) Disrupting B and T-cell collaboration in autoimmune disease: T-cell engagers versus CAR T-cell therapy? Clin Exper Immunology 217:15\u201330","journal-title":"Clin Exper Immunology"},{"key":"8211_CR77","doi-asserted-by":"crossref","unstructured":"Surowka M, Schaefer W, Klein C (2021) Ten years in making: applicationof CrossMab- technology for the development of therapeutic bispecific antibodies and antibody fusion proteins. mAbs 13:1967714","DOI":"10.1080\/19420862.2021.1967714"},{"key":"8211_CR78","doi-asserted-by":"publisher","first-page":"4785","DOI":"10.1158\/1078-0432.CCR-18-0455","volume":"24","author":"M Bacac","year":"2018","unstructured":"Bacac M, Colombetti S, Herter S, Sam J, Perro M, Chen S et al (2018) CD20-TCB with obinutuzumab pretreatment as next-generation treatment of hematologic malignancies. Clin Cancer Res 24:4785\u20134797","journal-title":"Clin Cancer Res"},{"key":"8211_CR79","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40364-021-00294-9","volume":"9","author":"S Zhou","year":"2021","unstructured":"Zhou S, Liu M, Ren F, Meng X, Yu J (2021) The landscape of bispecific T cell engager in cancer treatment. Biomarker Res 9:1\u201323","journal-title":"Biomarker Res"},{"issue":"523","key":"8211_CR80","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1038\/nature14468","volume":"2015","author":"EF McKinney","year":"2015","unstructured":"McKinney EF, Lee JC, Jayne DRW, Lyons PA, Smith KGC (2015) T-cell exhaustion, co-stimulation and clinical outcome in autoimmunity and infection. Nature 2015(523):612\u2013616","journal-title":"Nature"},{"key":"8211_CR81","doi-asserted-by":"publisher","unstructured":"Bot A, Scharenberg A, Friedman K, Guey L, Hofmeister R, Andorko JI, Klichinsky M, Neumann F, Shah JV, Swayer AJ, Trudeau K, Weissman D, Stephan MT, Buchholz CJ, June CH (2026) In vivo chimeric antigen receptor (CAR)-T cell therapy. Nat Rev Drug Discov. 25(2):116\u2013137. https:\/\/doi.org\/10.1038\/s41573-025-01291-5","DOI":"10.1038\/s41573-025-01291-5"},{"key":"8211_CR82","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1056\/NEJMc2509522","volume":"393","author":"Q Wang","year":"2025","unstructured":"Wang Q, Xiao ZX, Zheng X, Wang G, Yang L, Shi L et al (2025) In vivo CD19 CAR T-cell therapy for refractory systemic lupus erythematosus. N Engl J Med 393:15","journal-title":"N Engl J Med"},{"key":"8211_CR83","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2025.101354","author":"A-B Tigu","year":"2025","unstructured":"Tigu A-B, Nistor M, Gulei D, Constantinescu C-S, Kegyes D, Cenariu D et al (2025) CARing about autoimmune disorders. Use of chimeric antigen receptor engineered T-cells in autoimmune diseases. Blood Rev. https:\/\/doi.org\/10.1016\/j.blre.2025.101354","journal-title":"Blood Rev"},{"key":"8211_CR84","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1038\/nm.4148","volume":"22","author":"J He","year":"2016","unstructured":"He J, Zhang X, Wei Y, Sun X, Chen Y, Deng J et al (2016) Low-dose interleukin-2 treatment selectively modulates CD4+ T cell subsets in patients with systemic lupus erythematosus. Nat Med 22:991\u2013993","journal-title":"Nat Med"},{"key":"8211_CR85","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1136\/annrheumdis-2019-215396","volume":"79","author":"J He","year":"2020","unstructured":"He J, Zhang R, Shao M, Zhao M, Miao M, Chen J et al (2020) Efficacy and safety of low-dose IL-2 in the treatment of systemic lupus erythematosus: a randomized, double-blind, placebo-controlled trial. Ann Rheum Dis 79:141\u2013149","journal-title":"Ann Rheum Dis"},{"key":"8211_CR86","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1136\/ard-2022-222501","volume":"81","author":"JY Humrich","year":"2022","unstructured":"Humrich JY, Cacoub P, Rosenzwajg M, Pitoiset F, Pham HP, Guidoux J et al (2022) Low-dose interleukin-2 therapy in active systemic lupus erythematosus (LUPIL-2): a multicentre, double-blind, randomized and placebo-controlled phase II trial. Ann Rheum Dis 81:1685\u20131694","journal-title":"Ann Rheum Dis"},{"key":"8211_CR87","volume":"67","author":"R Ohno","year":"2024","unstructured":"Ohno R, Nakamura A (2024) Advancing autoimmune rheumatic disease treatment: CAR T-cell therapies \u2013evidence, safety, and future directions. Autoimmunity Rev 67:152479","journal-title":"Autoimmunity Rev"},{"key":"8211_CR88","doi-asserted-by":"publisher","unstructured":"Tigu AB, Nistor M, Gulei D, Constantinescu CS, Kegyes D, Cenariu D, Muresan X, Munteanu R, Feder R, Jitaru C, Bancos A, Santa M, Tomai R, Damian M, Ivancuta A, Rus I, Bojan A, Zdrenghea M, Buzoianu AD, Tanase A, Einsele H, Kobold S, Tomuleasa C (2026) CARing about autoimmune disorders. Use of chimeric antigen receptor engineered T-cells in autoimmune diseases. Blood Rev 75:101354. https:\/\/doi.org\/10.1016\/j.blre.2025.101354","DOI":"10.1016\/j.blre.2025.101354"},{"issue":"1","key":"8211_CR89","doi-asserted-by":"publisher","first-page":"2542","DOI":"10.1038\/s41467-024-46448-9","volume":"15","author":"M Doglio","year":"2024","unstructured":"Doglio M, Ugolini A, Bercher-Brayer C, Camisa B, Toma C, Norata R et al (2024) Regulatory T cells expressing CD19-targeted chimeric antigen receptor restore homeostasis in Systemic Lupus Erythematosus. Nat Commun 15(1):2542","journal-title":"Nat Commun"},{"key":"8211_CR90","doi-asserted-by":"publisher","first-page":"7015","DOI":"10.3390\/ijms21197015","volume":"21","author":"PJ Eggenhuizen","year":"2020","unstructured":"Eggenhuizen PJ, Ng BH, Ooi JD (2020) Treg enhancing therapies in treat autoimmune diseases. Int J Mol Sci 21:7015","journal-title":"Int J Mol Sci"},{"key":"8211_CR91","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2021.108409","volume":"102","author":"SA Beheshti","year":"2022","unstructured":"Beheshti SA, Shamsasenjan K, Ahmadi M, Abbasi B (2022) CAR Treg: a new approach in the treatment of autoimmune diseases. Int Immunopharmacol 102:108409","journal-title":"Int Immunopharmacol"},{"key":"8211_CR92","doi-asserted-by":"publisher","first-page":"4069","DOI":"10.1007\/s11033-022-07511-0","volume":"49","author":"FR Kahmini","year":"2022","unstructured":"Kahmini FR, Shahgaldi S (2022) Harnessing the inherent power of chimeric antigen receptor (CAR)- expressing regulatory T cells (CAR-Tregs) to treat autoimmune-related disorders. Mol Biol Rep 49:4069\u20134078","journal-title":"Mol Biol Rep"},{"key":"8211_CR93","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.clim.2018.04.006","volume":"192","author":"H Meng","year":"2018","unstructured":"Meng H, Sun X, Song Y, Zou J, An G, Jin Z et al (2018) La\/SSB chimeric autoantibody receptor modified NK92MI cells for targeted therapy of autoimmune disease. Clin Immunol 192:192\u2013240","journal-title":"Clin Immunol"},{"key":"8211_CR94","doi-asserted-by":"publisher","first-page":"2968","DOI":"10.1016\/S0140-6736(25)01671-X","volume":"406","author":"J Gao","year":"2026","unstructured":"Gao J, Li M, Sun M, Yu Y, Kong R, Xu X et al (2026) Efficacy and safety of allogeneic CD19 CAR NK-cell therapy in systemic lupus erythematosus: a case series in China. Lancet 406:2968\u20132979","journal-title":"Lancet"},{"key":"8211_CR95","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcyt.2026.102057","author":"M Nivet","year":"2024","unstructured":"Nivet M, Munia I, Crichi B et al (2024) Systemic lupus erythematosus patients eligible for chimeric antigen receptor T-cell therapy according to the 2024 EBMT and International Society for Cell and Gene Therapy expert-based recommendations: a 1-year clinical practice study in France. Cytotherapy. https:\/\/doi.org\/10.1016\/j.jcyt.2026.102057","journal-title":"Cytotherapy"},{"issue":"9","key":"8211_CR96","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1182\/blood.2025028375","volume":"146","author":"F M\u00fcller","year":"2025","unstructured":"M\u00fcller F, Schwingen NR, Hagen M, Scholz JK, Aigner M, Wirsching A et al (2025) Comparison of the safety profiles of CD19-targeting CAR T-cell therapy in patients with SLE and B-cell lymphoma. Blood 146(9):1088\u20131095","journal-title":"Blood"},{"issue":"4","key":"8211_CR97","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2025-005866","volume":"11","author":"EWY Hsieh","year":"2025","unstructured":"Hsieh EWY, Chung JB, Amin A, Askanase AD, Bartok B, Brunetta P, Lupus ABC CAR T Working Group et al (2025) Key considerations for advancing chimeric antigen receptor (CAR) T-cell therapy for systemic lupus erythematosus (SLE): a multi-partner\/disciplinary working group perspective. RMD Open 11(4):e005866","journal-title":"RMD Open"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-026-08211-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-026-08211-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-026-08211-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T05:02:20Z","timestamp":1787029340000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-026-08211-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,8]]},"references-count":97,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["8211"],"URL":"https:\/\/doi.org\/10.1007\/s10067-026-08211-x","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,8]]},"assertion":[{"value":"8 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 June 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This manuscript does not contain clinical studies or any patient data.","order":1,"name":"Ethics","label":"Ethics and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None.","order":3,"name":"Ethics","label":"Disclosures","group":{"name":"EthicsHeading","label":"Declarations"}}]}}